Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
8.25
-0.25 (-2.89%)
Mar 28, 2025, 12:45 PM EDT - Market open
Arcus Biosciences Revenue
In the year 2024, Arcus Biosciences had annual revenue of $258.00M with 120.51% growth. Arcus Biosciences had revenue of $26.00M in the quarter ending December 31, 2024, a decrease of -16.13%.
Revenue (ttm)
$258.00M
Revenue Growth
+120.51%
P/S Ratio
2.96
Revenue / Employee
$411,483
Employees
627
Market Cap
872.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
RCUS News
- 2 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 4 weeks ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update - Business Wire
- 5 weeks ago - Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering - Business Wire
- 5 weeks ago - Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock - Business Wire
- 5 weeks ago - New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Business Wire
- 6 weeks ago - Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium - Business Wire
- 2 months ago - Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer - Business Wire